608 results about "Bacterosira" patented technology

The invention relates to a method for treating nitrogen and phosphorus-containing cleaning wastewater, which comprises the following steps: adding residual activated sludge, activated carbon and a nitrogen and phosphorus removal bacterial agent into a treatment system, carrying out braising exposure treatment, and regularly adding an organic carbon source; the nitrogen and phosphorus removal bacterial agent at least contains microbacterium kitamiense (PR) and aeromicrobe (Aeromicrobe tamlense) (PW), and is characterized in that the nitrogen and phosphorus removal bacterial agent at least contains the microbacterium kitamiense (PR) and the aeromicrobe tamlense (PW); the preservation numbers of the strain are respectively CGMCC (China General Microbiological Culture Collection Center) No. 25182 and CGMCC No. Starting water feeding after braising exposure is finished, and continuously operating to treat the cleaning wastewater. According to the method, total nitrogen, total phosphorus and COD in the wastewater can be efficiently removed at the same time in one structure, the treatment burden of a subsequent biochemical unit is avoided, the process is simple, and the cost is low.

The invention discloses a transcription factor Cgl2988 related to production of 5-aminolevulinic acid based on network model prediction and application, the amino acid sequence of the transcription factor Cgl2988 is as shown in SEQ ID NO.1. The transcription factor Cgl2988 related to production of 5-ALA is simulated and predicted based on a metabolic network model system mcCGL, and experiments prove that the transcription factor Cgl2988 related to production of 5-ALA has the advantages that the transcription factor Cgl2988 related to production of 5-ALA can be used for preparing the transcription factor Cgl2988 related to production of 5-ALA; the expression strain Cgh3-low-cgl2988 of the transcription factor gene cgl2988 in the down-regulated corynebacterium glutamicum is subjected to shake flask fermentation, and the yield of 5-ALA is 5.52 + / -0.19 g / L and is increased by about 1.64 times compared with that of a control strain; the expression strain Cgh3-pX-cgl2988 of the transcription factor gene cgl2988 in the up-regulated corynebacterium glutamicum is subjected to shake flask fermentation, and the yield of the 5-ALA is 5.76 + / -0.11 g / L, which is about 2.84 times higher than that of a control strain.

The invention provides common bacteroides and application thereof. Specifically, a strain of common bacteroides capable of producing 3-indolepropionic acid is separated from human feces for the first time, and the strain of common bacteroides is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, and the preservation number is CGMCC NO.46398. The strain of common bacteroides can be used for producing 3-indolepropionic acid, and the strain of common bacteroides can be used for producing 3-indolepropionic acid. Furthermore, the invention provides an application of the common bacteroides disclosed by the invention in production of 3-indolepropionic acid. Furthermore, the invention provides a method for producing the 3-indolepropionic acid by using the common bacteroides disclosed by the invention, and an application of the common bacteroides disclosed by the invention in increasing the content of the 3-indolepropionic acid in an organism.

The invention relates to the technical field of microorganisms, and particularly discloses a fermentation method of bifidobacterium longum BBMN68 as well as a fermented product, a postbiotic and application of the fermented product. According to the method for fermenting the bifidobacterium longum BBMN68, a fermentation substrate comprises alkaline protease hydrolyzed milk and a pomelo peel extract; the hydrolysis rate of the alkaline protease hydrolyzed milk is 9-11%, and the water-soluble dietary fiber content of the shaddock peel extract is 75-80%; the mass ratio of the alkaline protease hydrolyzed milk to the shaddock peel extract is (10-15): (1-3). The content of active ingredients in the fermented product prepared by the method is high, and after the fermented product is prepared into the postbiotics to be taken, the immune function of an organism can be recovered, immune organ damage is reduced, inflammation is relieved, and intestinal flora is regulated and controlled.

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention provides Eubacterium mucilaginosus E11405 and an application thereof. The invention provides Eubacterium mucus E11405, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the Eubacterium mucus E11405 is CGMCC No.31231. The invention further provides a preparation method of the Eubacterium mucus E11405. The inventor of the application studies the effect and mechanism of the Eubacterium mucus E11405 in relieving the mouse colorectal cancer, and the result shows that the Eubacterium mucus E11405 has a remarkable relieving effect on the mouse colorectal cancer, and can be used as a probiotic preparation for relieving the colorectal cancer. The Eubacterium mucilaginosus E11405 provides a new strategy for prevention and treatment of colorectal cancer-based digestive tract tumors, has potential clinical application prospects, and is expected to become an effective medicine for treating colorectal cancer-based digestive tract tumors.

The invention discloses bifidobacterium longum subsp.infantis capable of promoting bone growth and a metagen thereof, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1445 provided by the invention can promote the increase of bone volume fraction, femoral bone trabecula thickness and far-end growth plate thickness of mammals in a growth period, reduce the levels of serum bone resorption markers I-type collagen amino-terminal peptide and tartrate-resistant acid phosphatase, improve the levels of serum bone alkaline phosphatase and parathyroid hormone, and improve the clinical application value of the bifidobacterium longum subsp. Infantis CCFM1445. And the relative abundance of the other bacteria in the intestinal flora and the levels of creatine and indole-3-lactic acid are increased. The thermally inactivated bifidobacterium longum subsp. Infantis CCFM1445 can promote the increase of the volume fraction of femoral bones and the number of bone trabecula of malnourished mice and improve the N-terminal propeptide level of serum I-type procollagen. Therefore, the medicine or health care product prepared from the bifidobacterium longum subsp. Infantis CCFM1445 can be used for assisting in regulating bone metabolism and bone mass, and has a wide market prospect.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

The invention discloses an application of an antibacterial peptide and an application of the antibacterial peptide in preparation of antibacterial drugs for treating carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the antibacterial peptide is characterized in that the sequence is w-r-r-w-k-r-w-w-r-r, and the sequence is shown in the description. All amino acids are D-type amino acids; the antibacterial peptide can be used as an antibacterial substance in wash supplies, food preservative additives, medical consumable antibacterial agents and cosmetics, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and good in in-vivo antibacterial activity. Particularly, the antibacterial peptide has broad-spectrum killing activity against carbapenem pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the cell survival rate of the antibacterial peptide within the range of medium and low concentration (2 mu g / mL-32 mu g / mL) reaches half or more, the toxicity is small, the toxicity is almost avoided, the operability is high, and the antibacterial peptide can be widely applied to the field of medical application. The cost is low.

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.

The invention discloses a polypeptide derived from deep sea microorganisms, and belongs to the technical field of peptide inhibitors. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1; the polypeptide has a bacteriostatic and / or bactericidal function. The polypeptide can inhibit the growth of acinetobacter baumannii at 8 [mu] M and inhibit the growth of escherichia coli and multi-drug-resistant acinetobacter baumannii at 16 [mu] M, and can be used for preparing products with bacteriostatic and / or bactericidal performance, such as food, daily necessities or medical products.

A Bifidobacterium longum subsp. infantis YLGB-1496 postbiotic product, a bacteriocin, a preparation method, and a use, specifically relating to the technical field of probiotic postbiotics. The provided probiotic postbiotic product has the following biological functions: enhancing the intestinal barrier function, preventing and / or treating inflammatory bowel diseases, regulating gut flora, relieving intestinal flatulence and resisting oxidation, and has application prospects in preparing health-care foods or drugs for regulating gut flora and resisting oxidation.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The invention relates to a brand-new microbial natural metabolite, namely Fcl-8, which is derived from a fermentation solution of Xenorhabdius budapestensis XBD8, and is characterized in that the Fcl-8 is a new microbial natural metabolite, namely Fcl-8, which is derived from the fermentation solution of the Xenorhabdius budapestensis XBD8. The purified Fcl-8 is a snow white flocculent crystal and is very easy to dissolve in water, and the solid state of the purified Fcl-8 is as shown in Figure 1. The chemical structural formula of the Fcl-8 is as shown in a figure 2, the chemical formula is C57H102N14O12, the molecular weight is 1175.78744, and the typical secondary mass spectrum information of the Fcl-8 is as shown in a figure 3. The Fcl-8 is derived from a microbial natural metabolite, is novel in structure and high in biological activity, and has very high potential to be developed into a novel biopesticide.

The invention belongs to the technical field of bioengineering, and particularly relates to a sucrose phosphorylase mutant and application thereof in synthesis of 2-O-alpha-D-glucopyranosyl-L-ascorbic acid. The sucrose phosphorylase mutant is obtained by simultaneously mutating multiple sites of amino acids at the 91st site, the 154th site, the 185th site, the 323rd site and the 424th site of wild sucrose phosphorylase derived from Bifidobacterium pseudolongum, so that the efficiency of producing 2-O-alpha-D-glucopyranosyl-L-ascorbic acid by taking sucrose and vitamin C as raw materials is remarkably improved; only 15 hours are needed for completely catalyzing 1.2 M of vitamin C to produce 2-O-alpha-D-glucopyranosyl-L-ascorbic acid; and the yield of the 2-O-alpha-D-glucopyranosyl-L-ascorbic acid reaches 358 g / L. Therefore, the 2-O-alpha-D-glucopyranosyl-L-ascorbic acid has an important application value in the field of production of the 2-O-alpha-D-

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention relates to the technical field of microorganisms, and particularly discloses bifidobacterium adolescentis AGE17 capable of promoting growth and development of muscles and bones and application of the bifidobacterium adolescentis AGE17. The bifidobacterium adolescentis AGE17 is separated from excrement of healthy children and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.33452, and the preservation date is January 17, 2025. The bifidobacterium adolescentis AGE17 has the advantages that the bifidobacterium adolescentis AGE17 can be used for preparing the biological organic fertilizer; animal experiments prove that the bifidobacterium adolescentis strain AGE17 provided by the invention has the function of promoting muscle and skeletal development, has more obvious and prominent effects compared with a model strain bifidobacterium adolescentis ATCC15703, and has important application value in increasing the muscle strength and height of children and adolescents.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention discloses bifidobacterium longum subsp. Infantis BIN31 for regulating immunity as well as application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a bifidobacterium longum subsp. Infantis BIN31, the preservation number of which is CGMCC (China General Microbiological Culture Collection Center) No. 33422, and the preservation number of the bifidobacterium longum subsp. Infantis BIN31 is CGMCC No. 33422. The invention also provides an application of the strain in preparation of food for enhancing immune function, and / or food with an auxiliary protection function on intestinal barrier, and / or food for regulating intestinal flora function, and / or a bacteriostatic agent, and also provides an application of the strain in preparation of food for enhancing immune function, and / or food with an auxiliary protection function on intestinal barrier, and / or food for regulating intestinal flora function. The invention also discloses a bacteriostatic agent and an in-vitro bacteriostatic method based on the strain, which have the functions of enhancing immune function, assisting in protecting intestinal barriers and regulating intestinal flora. The bifidobacterium longum subsp. Infantis BIN31 disclosed by the invention can effectively assist in protecting intestinal barriers, regulating intestinal flora, enhancing immunity and realizing broad-spectrum bacteriostasis.

Provided is a Bifidobacterium breve for improving an aging-related cognitive disorder and use thereof. The Bifidobacterium breve for improving the aging-related cognitive disorder is named Bifidobacterium breve BBr16 strain with a deposit number CGMCC No. 24471. The strain can significantly improve the aging-related cognitive disorder and can be used for preparing a product with an efficacy of preventing, improving or treating the aging-related cognitive disorder.

The invention discloses a metagen prepared from bifidobacterium adolescentis and used for promoting synthesis of host collagen, and belongs to the technical field of microorganisms and medicines. The metagen of the bifidobacterium adolescentis CCFM1386 provided by the invention has a good effect of promoting synthesis of host collagen, improves moisture and elasticity of skin, and meanwhile, can improve the antioxidant capacity of the skin and maintain the stable state of collagen. The method specifically comprises the following steps: promoting the enzyme activity of the HSF cell LH1 in vitro by a thallus lysate, and improving the content of COL I and COL III and the enzyme activity of the LH1 in vitro from a fermented supernatant; the bifidobacterium adolescentis has the advantages that the content of collagen is increased by orally taking inactivated thalli, the enzyme activity of LH1, P4H and LOX can be improved by orally taking self-fermentation supernate, the synthesis of the collagen is promoted, and the content of the collagen is increased, so that the bifidobacterium adolescentis has huge application prospects in preparation of oral medicines for promoting the synthesis of host collagen and preparation of foods, health-care products or cosmetics.

The invention discloses a preparation method of nano ozone water and application of the nano ozone water in killing food-borne pathogenic bacteria, and belongs to the technical field of bactericides. The nano ozone water is prepared by utilizing the ultra-fine bubble generator and the ozone generator, and the prepared nano ozone water is high in stability, not easy to decompose and high in practicability. The nano ozone water can achieve an effective killing effect on escherichia coli, salmonella, enterococcus, campylobacter and clinical multi-drug-resistant bacteria thereof, and a new resource is provided for preparing a safe and reliable antibacterial product.

The present invention provides a novel resource-recycling technology for converting crustacean waste into violacein. Specifically, an engineered strain of Viola viride that efficiently metabolizes chitin and synthesizes violacein is disclosed. The engineered strain can be used for crustacean waste treatment and chitin resource conversion.

The present disclosure relates to the field of cosmetics, and particularly to Bifidobacterium longum subsp. infantis, a microbial agent and use thereof. The present disclosure provides Bifidobacterium longum subsp. infantis, with preservation No. CGMCC NO. 27851. A species related to in the present disclosure can achieve efficacies of repairing, anti-inflammation, whitening and the like in food and beauty fields, has a wider range of efficacies, and can play a better role in the field of beauty and skin care.

The invention belongs to the technical field of microorganisms, and discloses a riemerella anatipestifer bacteriophage PT56, a bacteriophage composition thereof and application of the riemerella anatipestifer bacteriophage PT56, the collection number of the riemerella anatipestifer bacteriophage PT56 is CGMCCNO.46492, and the riemerella anatipestifer bacteriophage PT56 is collected in China General Microbiological Culture Collection Center on May 26, 2025, and the collection number is CGMCCNO.46492. The preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The riemerella anatipestifer bacteriophage PT56 has broad-spectrum bactericidal ability on riemerella anatipestifer of different serotypes, has certain temperature stability and acid-base stability, and can be used as an active ingredient for preparing drugs, disinfectants, kits and the like for preventing and treating riemerella anatipestifer diseases. The riemerella anatipestifer disinfection solution is widely applied to poultry diseases caused by riemerella anatipestifer and disinfection and sterilization of each link in the product production and processing process, is safe to use, and effectively reduces the incidence rate and the death rate of riemerella anatipestifer diseases such as poultry infectious serositis and the like.

The invention discloses a microbial inoculum for inhibiting beet root rot and application of the microbial inoculum, the microbial inoculum is obtained by fermenting brevibacterium alimentarius, the microbial inoculum has the remarkable characteristics of saline-alkaline tolerance, high viable count and the like, and the yield loss caused by diseases can be reduced by effectively preventing and treating the beet root rot, so that the yield and quality of crops are improved. After the fungicide is used for treatment, in normal soil, the seed germination rate and morbidity are different from those of a control group. Particularly, in disease nursery soil, the germination rate of the seeds can be remarkably increased and the morbidity can be reduced by treating the seeds with the bacterial liquid. The microbial agent provided by the invention not only reduces the investment cost of chemical pesticides, but also can improve the yield and quality of crops, and brings higher economic benefits. In addition, the biological agent is environment-friendly, is beneficial to maintaining the health and stability of a soil ecosystem, and promotes the sustainable development of agriculture.

The invention relates to the technical field of biological medicine, and discloses bifidobacterium adolescentis YF-01 and application thereof in fermented milk. The bifidobacterium adolescentis YF-01 is separated from adult excrement and is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 20251308. Experiments prove that the bifidobacterium adolescentis YF-01 has good gastrointestinal fluid tolerance, the survival rate of the bifidobacterium adolescentis YF-01 can reach 90.1% after simulated gastric fluid treatment for 3 h, and the survival rate of the bifidobacterium adolescentis YF-01 can reach 72% after simulated intestinal fluid treatment for 4 h The strain has the self-aggregation rate of 88.83% and the hydrophobicity of 79.41%, has remarkable scavenging capacity on DPPH free radicals and hydroxyl free radicals, shows good antioxidant activity and adhesion capacity, and provides a theoretical basis for application of the strain in fermented milk. The strain and metabolites thereof can be used for preparing food, medicines or health care products capable of regulating intestinal flora and enhancing oxidation resistance, and have remarkable application potential in development of functional fermented milk products.

The invention relates to a biomarker for screening intestinal flora transplantation donors and application of the biomarker. The biomarker comprises intestinal flora and metabolites thereof, the intestinal flora comprises phylum firmicalis, bacteroides and the like, and the metabolites comprise short-chain fatty acid, tryptophan, indole, 5-hydroxytryptamine, lipopolysaccharide and the like. According to the method, the intestinal flora of different crowds is deeply analyzed, the relationship between each related index of the intestinal flora and the intestinal flora transplantation effect is studied, sufficient clinical verification is carried out, a biomarker for screening the intestinal flora transplantation donor is excavated, and a standard for judging whether the intestinal flora transplantation donor is qualified or not is established; and a new method and a new idea are provided for efficiently and accurately screening intestinal flora transplantation donors.

The invention relates to the technical field of microorganisms, in particular to a citrobacter welchii bacteriophage as well as a composition and application thereof. The name of the citrobacter werkmanii bacteriophage is RDP-CI25012, the citrobacter werkmanii bacteriophage is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on August 25, 2025, and the preservation number of the citrobacter werkmanii bacteriophage is CGMCC (China General Microbiological Culture Collection Center) No. 46668. The composition comprises the bacteriophage. The bacteriophage or the composition is prepared in the following steps: (1) preparing a product for killing citrobacter welchii; (2) preparing a product for inhibiting citrobacter welchii; and (3) application in preparation of a product for preventing and / or treating citrobacter welchii disease caused by citrobacter welchii. The cracking rate of the phage is 80%, and the phage has an extremely high host range and a relatively wide cracking spectrum. After the bacteriophage is treated at 50 DEG C for 4 hours, the titer is still kept at 107 PFU / mL or above, and the bacteriophage has excellent thermal stability, so that a solid foundation is laid for use, storage, transportation and production processing of the bacteriophage in most practical application scenes.

The invention relates to an alkali-resistant massinia sp., in particular to a separated alkali-resistant massinia sp. P2-6 with broad-spectrum phagocytosis activity on pathogenic bacteria, and the alkali-resistant massinia sp. P2-6 is used for phagocytosis in a bacterium splitting manner, and can be used for preparing the alkali-resistant massinia sp. P2-6 with broad-spectrum phagocytosis activity on pathogenic bacteria. The compound has phagocytosis activity on pathogenic bacteria such as aeromonas veronii, aeromonas hydrophila, aeromonas cainea, pseudomonas aeruginosa, shewanella alginate or photobacterium damsela and the like; the alkali-resistant Marsinia sp. P2-6 disclosed by the invention can be applied to inhibition of pathogenic bacteria in an aquaculture water body; alkali-resisting marssonia sp. P2-6 or a microbial agent thereof is added into an aquaculture feed, so that the organism immunity and / or oxidation resistance and / or disease infection resistance of aquaculture animals can be enhanced; the alkali-resistant Marsinia sp. P2-6 provided by the invention can be used as a feed additive for aquaculture or a biocontrol product for aquaculture, and can also be used for preventing and / or treating diseases of aquaculture animals.